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Abstract 
       Ischemic stroke (IS) due to giant cell arteritis (GCA) is rare, but highly mortal. 
Here we report a 72-year-old man who showed frequent IS with GCA. Initial therapy with 
prednisolone increased the frequency of IS, which disappeared after continuous multi-
modal combination therapy with corticosteroids, immunosuppressive agents, antiplatelets, 
and statin. The present case was discharged with independent walk, suggesting that a multi-
modal combination therapy rescued the GCA patient from frequent IS. 
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1 Introduction 
        Cerebrovascular ischemic strokes (IS), which have been reported in 4 - 6 % of 
patients with giant cell arteritis (GCA), are the leading cause of mortality.1 Here we report 
a case of frequent IS due to GCA which usually develops a serious course, but was rescued 
by multi-modal therapy with corticosteroids, immunosuppressive agents, antiplatelets, and 
statin. 
 
2 Case report 
        A man had been on medication for diabetes and hyperlipidemia from the age of 
45. When he was 72 years old, he suddenly experienced dysarthria and right hemiparesis, 
which spontaneously disappeared 90 min after onset. Upon visiting our emergency clinic, 
he was admitted to our hospital. He showed a normal body temperature (36.1 ℃) and no 
neurological deficits. Laboratory tests revealed a moderately elevated erythrocyte 
sedimentation rate (ESR, 38/71 mm). Brain magnetic resonance imaging (MRI) showed 
no high intensity area (HIA) with diffusion–weighted image (DWI, Fig. 1Aa). On the other 
hand, MR angiography (MRA) showed severe stenosis at the supraclinoid portion of the 
bilateral internal carotid arteries (ICAs, Fig. 1Ab, arrows). On day 4 of admission, he again 
presented transient right hemiparesis, when DWI showed HIA in the left frontal lobe (Fig. 
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1Ac, arrows), and was thus temporarily diagnosed with atherothrombotic stroke. He was 
discharged on day 28 after prescribing aspirin (100 mg) and pravastatin (5 mg). 
        However, he experienced transient aphasia and right upper limb paresis without 
any new lesions on DWI at 7 days after discharge, and was again admitted to our hospital. 
Based on recurrent IS with persistently high inflammatory responses, we suspected 
cervical/intracranial vasculitis. Gadolinium (Gd)-enhanced brain MRI showed intramural 
enhancement in both terminal ICAs (Fig. 1Ad, e, arrowheads) and in the superficial 
temporal artery (STA) (Fig. 1Af, g, arrowheads). T2 star-weighted image (T2*WI) showed 
no intracranial microbleeds (not shown). Digital subtraction angiography (DSA) showed 
that the smoothly tapered vascular stenosis at the supraclinoid portions of ICA (Fig. 1B, 
arrow) without middle cerebral artery (MCA) stenosis, and the decreased blood flow 
velocity in distal part from the supraclinoid portions. A 18F-fluoro-2-deoxy-2-d-glucose 
(18F-FDG) positron emission tomography (PET)/computed tomography (CT) scan showed 
increased uptake in bilateral common carotid arteries, the right subclavian artery, and the 
aortic arch (Fig. 1Ca-d, arrows). An STA biopsy on day 12 of the second admission showed 
significant intimal thickening (Fig. 1Da, arrows), epithelioid granuloma (Fig. 1Db, arrows), 
and giant cell formation (Fig. 1Dc, arrows). 
        The patient was thus diagnosed with recurrent IS due to GCA, and was treated 
with prednisolone (PSL, 60 mg) and cyclophosphamide (CPA, 500 mg). Although ESR 
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decreased immediately to a normal range after this combination therapy, carotid artery 
ultrasound showed a gradual increase of intima-media thickness (IMT) and a reduction in 
end diastolic velocity (EDV) of the ICA (Fig. 1E, upper columns). He developed at least 
10 TIAs and four strokes (Fig. 1E, middle column) within 4 weeks, and his gait disturbance 
and frontal lobe function gradually worsened (frontal assessment battery (FAB); from 
17/18 on the second admission to 5/18 on day 35). However, such frequent ischemic 
attacks disappeared soon after replacing pravastatin (5 mg) with atorvastatin (10 mg) on 
day 47 followed by antiplatelet oral cilostazol (50 – 100 mg) and ozagrel infusion (80 mg) 
from day 53, and methotrexate (6 mg/week) from day 66. On day 108, he was discharged, 
walked independently, and FAB recovered to 17/18. 
 
3 Discussion 
        The present case showed frequent IS with intracranial artery stenosis due to GCA, 
but was successfully rescued by combination therapy of steroids, immunosuppressants, 
antiplatelets, and statin. Although the present case had not showed typical clinical 
symptoms of GCA such as headache, jaw claudiation, and enlarged temporal artery, these 
symptoms’ sensitivities were low.2 The positive temporal artery biopsy and the findings of 
inflammatory in the large arteries on MRI and 18F-FDG PET/CT scan were also important 
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findings for meeting the criteria of GCA as well as specific clinical symptoms.3 Thus, he 
was diagnosed with GCA.  
        MRA of the present case depicted poorer MCA related with worsened his 
symptoms. On the other hand, DSA showed the severe stenosis at the supraclinoid portions 
of ICA without MCA stenosis (Fig. 1B, arrow). Decreased arterial signal on MCA might 
be caused by the hypoperfusion of MCA due to ICA stenosis. Furthermore, the reversible 
arterial wall thickening after treatment on enhanced MRI suggested vasculitis (Fig. 1E, 
lower column). Although cerebral infarction at corona radiate was atypical for GCA, the 
previous report showed that partial internal watershed infarction was associated with 
hemodynamic impairment with ICA steno-occlusion.4 These results suggested that the 
main pathological mechanism of the present case was hemodynamic etiology caused by 
bilateral ICA stenosis due to GCA. 
        High-dose glucocorticoid therapy is well established for the treatment of IS due 
to GCA, and antiplatelet and statin therapy may also be effective.5, 6 However, in the 
present case, IS frequency increased and both IMT and EDV worsened (Fig. 1E), even 
after steroid therapy. Steroid therapy might not rapidly improve the organized intima 
thickening, may even activate platelet thromboxane, and promotes vascular occlusion.7 On 
the other hand, a combination of corticosteroids plus immunosuppressive agents or 
antiplatelet therapy appears to be beneficial in patients with IS due to GCA.1, 5 Furthermore, 
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cilostazol shows not only an antiplatelet but also a vasodilatory effect by inhibiting 
phosphodiesterase 3, subsequently raising the level of intracellular cAMP.8 In fact, the 
present case showed a gradual improvement of IMT and EDV ultrasound findings as well 
as improved symptoms after continuous multi-modal therapy including additional 
cilostazol therapy (50 – 100 mg) (Fig. 1E). Although the second administration of 
cyclophosphamide might be effective, the first administration of cyclophosphamide was 
not effective. Therefore, we considered that the vasodilatory effect of cilostazol was 
clinically more effective. 
        IS due to GCA is rare and shows a mortality rate as high as 53%.1 However, the 
present case suggests that multi-modal combination therapy was able to rescue GCA 
patient with frequent IS with ITAs and lacunes. 
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Figure legend 
Fig. 1) (A) MRI and MRA on day 1 (a, b) of first admission, showing no HIA on DWI (a), 
severe stenosis in the supraclinoid portion of the bilateral ICAs (b, arrows). DWI on day 4 
of the first admission showed HIAs in the left corona radiata (c, arrows). Axial (d, f, g) and 
sagittal (e) gadolinium-enhanced T1-weighted vessel wall MRI on day 5 of the second 
admission, showing intramural enhancement and thickening in both terminal ICAs (d, e, 
arrowheads) and STA (f, g, arrowheads). (B) DSA showed the smoothly tapered vascular 
stenosis at the supraclinoid portions of ICA (arrow), but without MCA stenosis. (C) 18F-
FDG PET/CT scan, showing increased uptake in bilateral CCAs (a, b, arrows), the right 
subclavian artery (a, c, arrowheads), and the aortic arch (a, d, open arrowheads). (D) HE 
staining of right STA, showing significant intimal thickening (a, arrows), epithelioid 
granuloma (b, arrows), and giant cell formation (c, arrows). Scale bars: a-c = 200 µm. (E) 
Hospital course (ESR, carotid artery ultrasound, NIHSS, MRI and MRA) and medication 
of the patient during second admission. 
